- Home
- ALLO vs ARCT Comparison
ALLO vs ARCT Comparison
Compare ALLO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- ARCT
- Stock Information
- Founded
- ALLO 2017
- ARCT 2013
- Country
- ALLO United States
- ARCT United States
- Employees
- ALLO N/A
- ARCT N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- ALLO Health Care
- ARCT Health Care
- Exchange
- ALLO Nasdaq
- ARCT Nasdaq
- Market Cap
- ALLO 277.8M
- ARCT 298.3M
- IPO Year
- ALLO 2018
- ARCT N/A
- Fundamental
- Price
- ALLO $1.21
- ARCT $13.78
- Analyst Decision
- ALLO Strong Buy
- ARCT Strong Buy
- Analyst Count
- ALLO 9
- ARCT 8
- Target Price
- ALLO $8.44
- ARCT $52.83
- AVG Volume (30 Days)
- ALLO 2.5M
- ARCT 484.1K
- Earning Date
- ALLO 08-06-2025
- ARCT 08-04-2025
- Dividend Yield
- ALLO N/A
- ARCT N/A
- EPS Growth
- ALLO N/A
- ARCT N/A
- EPS
- ALLO N/A
- ARCT N/A
- Revenue
- ALLO N/A
- ARCT $143,680,000.00
- Revenue This Year
- ALLO N/A
- ARCT N/A
- Revenue Next Year
- ALLO $199.63
- ARCT $34.79
- P/E Ratio
- ALLO N/A
- ARCT N/A
- Revenue Growth
- ALLO N/A
- ARCT 15.38
- 52 Week Low
- ALLO $0.86
- ARCT $8.04
- 52 Week High
- ALLO $3.78
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- ALLO 43.73
- ARCT 58.14
- Support Level
- ALLO $1.11
- ARCT $12.65
- Resistance Level
- ALLO $1.29
- ARCT $14.09
- Average True Range (ATR)
- ALLO 0.09
- ARCT 0.94
- MACD
- ALLO -0.01
- ARCT 0.05
- Stochastic Oscillator
- ALLO 25.81
- ARCT 64.60
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.